Mohammed Hamid Osman Ali
ID: UNCST-2026-R024137
|
Harnessing Borassus Fruits as a Sustainable Source of Biofuels: A Techno-Economic Feasibility Study at Soroti University
REFNo: SIR726ES
Overall Objective
To evaluate and demonstrate the potential of Borassus tress as a sustainable source of renewable energy for Soroti University and its surrounding community by 2026.
Smart Specific Objectives
1. To analyze the chemical composition (sugar content, metals, calorific value and moisture) of Borassus fruits and sap, and quantify their potential yield for biofuels production.
2. To conduct bench scale, high precision sap to biofuel conversion through fractional distillation and refining.
3. To conduct a techno-economic feasibility assessment comparing Borassus-derived energy with current energy sources (national electricity grid, firewood and charcoal) used in Soroti University.
|
Sudan |
2026-07-17 17:09:06 |
2029-07-17 |
Engineering and Technology |
Non-Clinical Trial |
Non-degree Award |
|
Sam Ononge
ID: UNCST-2020-R000328
|
Evaluation of a self-monitoring tool to detect early obstetric complications in the immediate postpartum period: A validation study of the ImPoWa tool
REFNo: HS7770ES
Main Objective
1. To evaluate the validity of the ImPoWA tool in facilitate self-monitoring for early warning signs of an obstetric complication during the immediate postpartum period by women and their birth companions
Specific Objectives
1. To explore the accuracy of the mothers’ and companions’ assessments when using the tool
2. To ?Explore the reliability of mothers’ and companions’ assessments when using the tool in different clinical contexts and time periods
|
Uganda |
2026-07-17 17:05:51 |
2029-07-17 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Miriam Nakalembe
ID: UNCST-2021-R014040
|
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS (BEATRIX)
REFNo: HS8109ES
To describe GBS serotype-specific IgG concentrations measured from dried blood spots in a subset of infant participants at birth;
To describe anti-GBS antibodies present in breast milk in a subset of maternal participants vaccinated with GBS6
To describe serum IgG responses to active immunization with diphtheria toxoid�containing vaccine and PCV in infant participants born to maternal participants vaccinated with GBS6 versus placebo.
To describe PCV serotype-specific OPA titers after a toddler vaccination in infant participants born to maternal participants vaccinated with GBS6 or placebo.
To additionally describe the immune responses to CPS elicited by GBS6 when administered to healthy pregnant women.
To describe serum IgG responses to active immunization with diphtheria toxoid� containing vaccine and/or PCV in infant participants born to maternal participants vaccinated with GBS6 versus placebo.,To further describe the immunogenicity of GBS6 in maternal participants when administered to healthy pregnant women.
To describe anti-CPS IgG antibody levels predicted to provide protection from invasive GBS EOD and LOD, separately, caused by the 6 individual vaccine serotypes (Ia, Ib, II, III, IV, and V) in infants when GBS6 is administered to healthy pregnant women,To assess the ability of GBS6 to induce opsonophagocytic activity (OPA) titers at birth in infant participants born to maternal participants vaccinated with GBS6,To describe anti-CPS IgG antibody levels in infant participants born to maternal participants vaccinated with GBS6.
To describe anti-CPS IgG antibody levels predicted to provide protection from invasive GBS disease (all disease) caused by the 6 individual vaccine serotypes in infants when GBS6 is administered to healthy pregnant women,To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS EOD based on serotype-specific anti-CPS IgG concentrations measured in infants at birth,To evaluate the aggregate predicted VE combining all 6 serotypes in GBS6 to provide protection from invasive GBS LOD based on serotype-specific anti-CPS IgG concentrations measured in infants at birth.
To assess the ability of GBS6 to induce anti-CPS IgG antibody levels predicted to provide protection from invasive GBS early-onset disease (EOD) caused by the 6 individual vaccine serotypes (Ia, Ib, II III, IV, and V) in infants when GBS6 is administered to healthy pregnant women,To assess the ability of GBS6 to induce anti-CPS IgG antibody levels predicted to provide protection from invasive GBS late-onset disease (LOD) caused by the 6 individual vaccine serotypes (Ia, Ib, II III, IV, and V) in infants when GBS6 is administered to healthy pregnant women,To assess the safety of maternal immunization in infant participants born to pregnant women who were vaccinated with GBS6 during pregnancy. To describe the safety and tolerability of GBS6 in maternal participants
|
Uganda |
2026-07-17 17:00:50 |
2029-07-17 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Esther Nanfuka Kalule
ID:
|
EXPLORING ACCELERATING IMPACT FOR YOUNG WOMEN (AIM) PROGRAM COHORT # 2 AND # 3 LIVELIHOOD EXPERIENCES: A QUALITATIVE STUDY IN UGANDA
REFNo: SS5437ES
Main objective
This study seeks to explore the AIM financial inclusion journey for cohort #2 participants and progress thus far in the livelihoods pathway for those in cohort #3.
Specific objectives
1.To examine opportunities and challenges experienced by cohort #2 project participants and staff in transitioning participants to microfinance.
2.To identify opportunities and challenges experienced by cohort #3 project participants and staff during implementation of cost sharing and coaching elements of AIM 2.0.
3.To document cohort #2 and #3 participants’ perspectives on the impact of AIM on their lives.
|
Uganda |
2026-07-17 16:20:28 |
2029-07-17 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Isaac Ssewanyana
ID: UNCST-2020-R014336
|
ConfiSign HCV Self-Test: Evaluation of Clinical Performance and Usability in the hands of untrained users.
REFNo: HS8059ES
The product design, instructions for use and usability of the ConfiSign HCV Self-Test for self-testing will be assessed by investigation of the following secondary objectives: - Clarity and usability of instructions and packaging � participant-reported ease of understanding and following instructions, collected via a structured questionnaire. - Occurrence of user errors � frequency and type of errors and/or deviations from the test procedure observed during the study - Invalid test results � proportion of tests yielding invalid results due to user errors.,The primary and overall objective of this study is to evaluate the performance and the usability of the ConfiSign HCV Self-Test in the hands of untrained users, recruited in a high prevalence HCV region (> 2%), who have no or limited experience in self-testing. ,
|
Uganda |
2026-07-17 16:17:16 |
2029-07-17 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|